Dr. Faisal Shuaib, Executive Director, National Primary Health Care Development Agency (NPHCDA) has given an insight into the composition of COVID-19 vaccines.
In an interview on Monday, April 19, in Abuja, Shuaib said there were several COVID-19 vaccine candidates.
He said while some had been approved for emergency use by the World Health Organisation (WHO), others were still in different phases of clinical trials for possible approval.
According to him, COVID-19 vaccine candidates are of various categories based on their mechanism of action such as the inactivated or weakened virus vaccines.
The NPHCDA boss explained that in formulating the COVID-19 vaccine, an inactivated or weakened virus is used; so it does not cause disease, but generates an immune response.
He also said there were protein-based vaccines, which used harmless fragments of proteins or protein shells that mimic the COVID-19 virus to safely generate an immune response.
The NPHCDA boss added that the viral vector vaccines used a virus that had been genetically engineered; so that it could not cause disease but would produce coronavirus proteins to safely generate an immune response.
He added that the Ribonucleic Acid (RNA) and Deoxyribonucleic Acid (DNA) vaccines; employed a cutting-edge approach that used genetically engineered RNA or DNA; to generate a protein that safely prompted an immune response.